Intellia Therapeutics Broadcasts Closing of $201 Million Public Providing of Widespread Inventory, Together with Full Train of Underwriters’ Choice to Buy Extra Shares

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a number one genome enhancing firm centered on creating healing therapeutics utilizing CRISPR/Cas9 expertise each in vivo and ex vivo, introduced right this moment the closing of an underwritten public providing of 5,513,699 shares of its widespread inventory, together with the train in full by the underwriters of their choice to buy an extra 719,178 shares, on the public providing value of $36.50 per share. The gross proceeds raised within the providing, earlier than underwriting reductions and commissions and bills of the providing, have been roughly $201 million.

Goldman Sachs & Co. LLC, Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the providing.

The shares of widespread inventory have been provided by Intellia pursuant to a shelf registration assertion that was beforehand filed with the U.S. Securities and Alternate Fee (SEC) and mechanically grew to become efficient upon submitting. A ultimate prospectus complement and accompanying prospectus referring to and describing the phrases of the providing was filed with the SEC on December 2, 2020. The ultimate prospectus complement and accompanying prospectus referring to the providing could also be obtained from: Goldman Sachs & Co. LLC, by mail at 200 West Road, New York, NY 10282, Consideration: Prospectus Division, by phone at (866) 471-2526, or by e mail at prospectus-ny@ny.e mail.gs.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Flooring, New York, NY 10022, Consideration: Fairness Syndicate Prospectus Division, by phone at (877) 547-6340, or by e mail at Prospectus_Department@Jefferies.com; or SVB Leerink LLC, by mail at One Federal Road, thirty seventh Flooring, Boston, MA 02110, Consideration: Syndicate Division, by phone at (800) 808-7525, ext. 6132, or by e mail at syndicate@svbleerink.com; or by accessing the SEC’s web site at www.sec.gov.

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction during which such supply, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.

About Intellia Therapeutics

Intellia Therapeutics is a number one genome enhancing firm centered on creating proprietary, healing therapeutics utilizing the CRISPR/Cas9 system.

Ahead-Trying Statements

This press launch comprises forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements concerning Intellia’s anticipated public providing. The phrases “might,” “will,” “might,” “would,” “ought to,” “anticipate,” “plan,” “anticipate,” “intend,” “imagine,” “estimate,” “predict,” “mission,” “potential,” “proceed,” “goal” and comparable expressions are supposed to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Any forward-looking statements on this press launch are primarily based on administration’s present expectations and beliefs and are topic to a lot of dangers, uncertainties and necessary components which will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, uncertainties associated to market situations. These and different dangers and uncertainties are described in larger element within the part entitled “Threat Components” in Intellia’s most up-to-date annual report on Type 10-Okay and quarterly report on Type 10-Q filed with the SEC, in addition to discussions of potential dangers, uncertainties, and different necessary components in Intellia’s different filings with the SEC, together with these contained or included by reference within the ultimate prospectus complement and accompanying prospectus associated to the general public providing filed with the SEC. Any forward-looking statements contained on this press launch signify Intellia’s views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to replace any forward-looking statements, besides as required by regulation.

Intellia Contacts: 

Traders:
Lina Li
Affiliate Director
Investor Relations
+1 857-706-1612
lina.li@intelliatx.com

Media:
Jennifer Mound Smoter
Senior Vice President
Exterior Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com